Schizophrenia Pipeline Insight 2025: Comprehensive Analysis by DelveInsight

DelveInsight’s “Schizophrenia Pipeline Insight 2025” report delivers in-depth information on over 55 companies and more than 60 pipeline drugs shaping the Schizophrenia treatment landscape. It includes detailed Schizophrenia Pipeline drug profiles for both clinical and nonclinical stage products. Additionally, it evaluates Schizophrenia Pipeline Therapeutics by product type, development stage, administration route, and molecule type. The report also spotlights inactive pipeline products in this field.

Interested in the newest developments in the Schizophrenia Pipeline? Click here to discover the therapies and trials gaining attention @ Schizophrenia Pipeline Outlook Report

Key Insights from the Schizophrenia Pipeline Report

On October 12, 2025, Case Western Reserve University released a study suggesting a potential transformation in schizophrenia care, focusing on treatments that boost patients' capacity to understand social signals accurately.
DelveInsight’s Schizophrenia Pipeline report illustrates a vibrant arena with over 55 active participants advancing more than 60 pipeline therapies for Schizophrenia management.
Leading Schizophrenia Companies include Sunovion Pharmaceuticals, Denovo BioPharma, Karuna Therapeutics, Boehringer Ingelheim, Merck Sharp & Dohme, MapLight Therapeutics, Valentech LLC, Addex Therapeutics, Biodexa Pharmaceuticals, Autifony Therapeutics, Vanda Pharmaceuticals, Luye Pharma, Reviva Pharmaceuticals, SyneuRx, Avanir Pharmaceuticals, Newron Pharmaceuticals, Celon Pharma, Delpor, Zhejiang Jingxin Pharmaceutical, Sirtsei Pharmaceuticals, and more.
Promising Schizophrenia Therapies encompass Brexpiprazole, ICLEPERTIN (BI-425809), KarXT (Xanomeline-Trospium), NUPLAZID (pimavanserin), MK-5720, NaBen, Brilaroxazine (RP-5063), ULOTARONT (SEP-363856), LUVADAXISTAT (NBI 1165844/TAK 831), Roluperidone (MIN-101), BXCL501 80, TV-44749, Evenamide (NW-3509/NW-3509A), LYN-005 (risperidone, weekly), OKEDI (risperidone ISM), Emraclidine (CVL-231), and others.
Want to learn which companies are driving advancements in Schizophrenia? Explore the complete pipeline details @ Schizophrenia Clinical Trials Assessment

The Schizophrenia Pipeline Report offers a disease summary, pipeline overview, and therapeutic evaluation of major pipeline therapies in this area. It also addresses unmet needs related to Schizophrenia.

Schizophrenia Overview

Schizophrenia is a long-term, serious mental health condition impacting an individual's thoughts, emotions, and actions. It features psychotic episodes involving disruptions in thinking, perception, emotional reactions, and social engagement. It impacts roughly 1% of the global population and usually emerges in late teens or early adulthood. The precise origins of schizophrenia remain unclear, but they likely stem from a mix of genetic, environmental, and neurological influences.

Schizophrenia Emerging Drugs Profile

Ulotaront: Sunovion Pharmaceuticals
SEP-363856 acts as a TAAR1 agonist with 5-HT1A agonist properties, being explored for schizophrenia and related mental health disorders. Sunovion developed SEP-363856 through partnership with PsychoGenics, utilizing a mechanism-independent strategy via the in vivo phenotypic SmartCube platform and AI tools. Studies indicate that ulotaront leads to a more significant drop in baseline PANSS total scores compared to placebo. It also correlates with enhanced sleep quality versus placebo. The drug is currently in Phase III development for Schizophrenia treatment.

Emraclidine: Abbvie
Emraclidine is a selective M4 receptor PAM, targeting the M4 receptor to leverage its antipsychotic benefits while reducing drawbacks of broader muscarinic agonists. The firm sees emraclidine as a potential major breakthrough, given the muscarinic acetylcholine pathway's role in addressing neurotransmitter imbalances and psychosis. It stands as the sole selective M4 receptor PAM in clinical trials. The drug is presently in Phase II for Schizophrenia.

CY 6463: Cyclerion Therapeutics
CY6463 represents the inaugural CNS-penetrating sGC stimulator designed as a symptomatic and possibly disease-altering treatment for severe CNS disorders. The nitric oxide (NO)-soluble guanylate cyclase (sGC)-cyclic guanosine monophosphate (cGMP) pathway regulates vital physiological functions across the body. As an sGC stimulator, CY6463 functions as a positive allosteric modulator, enhancing sGC sensitivity to NO, boosting cGMP output, and amplifying natural NO signaling. By addressing NO-sGC-cGMP deficiencies, CY6463 and similar stimulators could offer wide-ranging benefits for enhancing cognition and function in individuals with serious CNS conditions. The drug is in Phase I for Schizophrenia.

If you're monitoring active Schizophrenia Clinical trials, this press release is essential. Click to view the innovations @ Schizophrenia Treatment Drugs

The Schizophrenia Pipeline report provides insights into:

• Detailed information on firms developing Schizophrenia therapies, including the total therapies per company.

• Various therapeutic candidates divided into early, mid, and late development phases for Schizophrenia care.

• Schizophrenia Companies engaged in targeted therapy development, with active and inactive (dormant or halted) initiatives.

• Schizophrenia Drugs in progress, categorized by development phase, delivery method, target receptor, monotherapy or combo therapy, distinct action mechanisms, and molecular structure.

• In-depth review of partnerships (corporate-corporate and corporate-academic), licensing deals, and funding for advancing the Schizophrenia market.

Schizophrenia Companies

Sunovion Pharmaceuticals, Denovo BioPharma, Karuna Therapeutics, Boehringer Ingelheim, Merck Sharp & Dohme, MapLight Therapeutics, Valentech LLC, Addex Therapeutics, Biodexa Pharmaceuticals, Autifony Therapeutics, Vanda Pharmaceuticals, Luye Pharma, Reviva Pharmaceuticals, SyneuRx, Avanir Pharmaceuticals, Newron Pharmaceuticals, Celon Pharma, Delpor, Zhejiang Jingxin Pharmaceutical, Sirtsei Pharmaceuticals and others.

Schizophrenia Pipeline report assesses pipeline drugs by Route of Administration. Products are grouped under various ROAs such as,

Intravenous
Subcutaneous
Oral
Intramuscular

Schizophrenia Products are classified by Molecule types such as,

Monoclonal antibody
Small molecule
Peptide

From novel drug contenders to competitive insights, the Schizophrenia Pipeline Report has it covered – explore now @ Schizophrenia Market Drivers and Barriers, and Future Perspectives

Scope of the Schizophrenia Pipeline Report

Coverage- Global
Schizophrenia Companies- Sunovion Pharmaceuticals, Denovo BioPharma, Karuna Therapeutics, Boehringer Ingelheim, Merck Sharp & Dohme, MapLight Therapeutics, Valentech LLC, Addex Therapeutics, Biodexa Pharmaceuticals, Autifony Therapeutics, Vanda Pharmaceuticals, Luye Pharma, Reviva Pharmaceuticals, SyneuRx, Avanir Pharmaceuticals, Newron Pharmaceuticals, Celon Pharma, Delpor, Zhejiang Jingxin Pharmaceutical, Sirtsei Pharmaceuticals and others.
Schizophrenia Therapies- Brexpiprazole, ICLEPERTIN (BI-425809), KarXT (Xanomeline-Trospium), NUPLAZID (pimavanserin), MK-5720, NaBen, Brilaroxazine (RP-5063), ULOTARONT (SEP-363856), LUVADAXISTAT (NBI 1165844/TAK 831), Roluperidone (MIN-101), BXCL501 80, TV-44749, Evenamide (NW-3509/NW-3509A), LYN-005 (risperidone, weekly), OKEDI (risperidone ISM), Emraclidine (CVL-231), and others.
Schizophrenia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Schizophrenia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay informed in Healthcare Research – uncover upcoming trends in the Schizophrenia Treatment field through this thorough review @ Schizophrenia Emerging Drugs and Major Players

Table of Contents

1. Introduction

2. Executive Summary

3. Schizophrenia: Overview

4. Pipeline Therapeutics

5. Therapeutic Assessment

6. Schizophrenia– DelveInsight’s Analytical Perspective

7. Late Stage Products (Phase III)

8. Ulotaront: Sunovion Pharmaceuticals

9. Drug profiles in the detailed report…..

10. Mid Stage Products (Phase II)

11. Emraclidine: Abbvie

12. Drug profiles in the detailed report…..

13. Early Stage Products (Phase I)

14. CY 6463: Cyclerion Therapeutics

15. Drug profiles in the detailed report…..

16. Preclinical and Discovery Stage Products

17. Drug Name: Company Name

18. Drug profiles in the detailed report…..

19. Inactive Products

20. Schizophrenia Key Companies

21. Schizophrenia Key Products

22. Schizophrenia- Unmet Needs

23. Schizophrenia- Market Drivers and Barriers

24. Schizophrenia- Future Perspectives and Conclusion

25. Schizophrenia Analyst Views

26. Schizophrenia Key Companies

27. Appendix

About Us

DelveInsight is a premier healthcare market research and consulting firm delivering top-tier market intelligence and analysis to guide strategic decisions. With a skilled team of industry specialists and profound knowledge of life sciences and healthcare, we provide tailored research solutions and insights worldwide. Reach out for reliable, precise, and timely intelligence to lead the growth trajectory.

Contact Us

Kanishk

kkumar@delveinsight.com